KRAS and pancreatic intraductal papillary-mucinous neoplasm: Figura et al. reported that loss of Brg1 by mutation of Kras resulted in human IPMN-like lesions, implicating a distinct mechanism in IPMN development other than the Kras-driven carcinogenic pathway27.